Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have ...

Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 ...

Neoadjuvant immunotherapy plus chemotherapy shows a 35% pathological complete response rate and 49% major pathological response rate in LS-SCLC. Most patients achieved R0 surgical resection, with a 44 ...

Circulating tumor DNA dynamics and pathologic response to neoadjuvant immunotherapy in resectable stage III melanoma. Effect of chemotherapy drug cisplatin on the efficacy of B7H3 CAR-T cells in ...

The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...

The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...

The results of the phase 3 ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided ...

Immune checkpoint inhibitor (ICI) therapy before surgery for hepatocellular carcinoma (HCC) may produce major pathological response in about one-third of the surgical patients. The clinical and ...

In a national cohort study of patients with resectable head and neck squamous cell carcinoma (HNSCC), the number receiving neoadjuvant immunotherapy began to rise markedly in 2013, while use of ...